TICKERNERD
Menu
EXOZEXOZHealthcare · Biotechnology

EXOZ Stock Forecast: eXoZymes, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$5.52
−4.33% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 3 Oct 2026 — in the weakest quartile.

Market cap
$53.7M
Ticker Nerd rank
13 / 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$3.0M
Net income−$2.9M
Free cash flow−$1.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.0%
1M
−19.4%
YTD
−49.4%
1Y
−58.5%
From 52W high
−66.5%
From 52W low
+25.5%
$4
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EXOZ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores eXoZymes, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
13 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
90
Size
81
Issuance
54
Revisions
28
Volatility
15
Momentum
10
Value
7
Growth
6
Quality
3

Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EXOZ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EXOZ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14$16Jan 26Apr 26Jul 26Oct 26EXOZ

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EXOZ appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

EXOZ vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, eXoZymes, Inc. returned −58.5% against +17.0% for the S&P 500, dividends included.

EXOZ vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26EXOZS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EXOZ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

eXoZymes, Inc. (EXOZ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.6×

Cheaper than 90% of US stocks

Price / sales
—
Price / book
14.6×

Cheaper than 7% of US stocks

EV / EBITDA
−4.8×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−187.2%

Higher than 8% of US stocks

Return on assets
−74.7%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

eXoZymes, Inc. (EXOZ) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • eXoZymes, Inc. has a market value of $53.7M and an enterprise value of $49.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$10.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$7.1M.

  • Shares outstanding: 9.3M.

  • Trailing P/E: −5.6×.

  • eXoZymes, Inc. employs 32 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Oct 2026

Data provided by Twelve Data

Peers

EXOZ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EXOZeXoZymes, Inc.$53.7M
13
IMAImageneBio, Inc.$54.3M
26
EDSAEdesa Biotech, Inc.$52.2M
50
CELUCelularity, Inc.$51.9M
30
INMBINmune Bio, Inc.$51.3M
53
HYPDHyperion DeFi, Inc.$56.5M
40
KLRSKalaris Therapeutics, Inc.$56.6M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own eXoZymes, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EXOZ news & analysis

Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"

TheNewswire · 2 Oct 2026neutral

Water Tower Research published an Initiation of Coverage Report on eXoZymes, Inc. (NASDAQ: EXOZ) titled "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity." The report covers the company's cell-free biomanufacturing systems based on engineered enzymes, its history from UCLA research and Invizyne Technologies, its November 2024 IPO, and its pre-revenue status with commercialization expected next year.

Why it matters — A new initiation-of-coverage report from Water Tower Research provides external analyst visibility into eXoZymes' business model and its path toward expected commercialization.

eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT

Accesswire · 8 Sept 2026positive

eXoZymes announced it has entered into an agreement with Curia Global for commercial-scale manufacturing of its NCT process, with the program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027. The agreement advances the NCT manufacturing process from pilot-scale validation toward commercial manufacturing.

Why it matters — A watcher of eXoZymes would find this significant because it marks a key progression of the company's NCT process toward commercial launch by establishing a manufacturing pathway and supply chain.

eXoZymes Q2 Earnings Call Highlights

MarketBeat · 20 Aug 2026positive

On its Q2 earnings call, eXoZymes outlined progress toward commercializing its NCT program, reporting a tenfold increase in process productivity versus its March pilot campaign. Management said it expects to select a manufacturing partner by the end of the third quarter and identify a market launch partner toward the end of the fourth quarter.

Why it matters — For eXoZymes watchers, the reported productivity gains and the announced timelines for choosing manufacturing and launch partners signal tangible advancement toward commercializing its NCT program.

eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today

Accesswire · 20 Aug 2026neutral

eXoZymes will report its second quarter 2026 results and host an investor webinar at 5:00 PM Eastern Time on August 20, 2026, to discuss the period ended June 30, 2026 and provide updates on recent business developments.

Why it matters — If eXoZymes watchers missed the release, the webinar will be their source for the company's quarterly financial results and latest business progress.

eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets

Accesswire · 18 Aug 2026positive

eXoZymes reported that its NCT process achieved a 10-fold productivity increase, improving the estimated economics of future commercial-scale manufacturing. According to internal assessments, the estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized version.

Why it matters — The improved NCT process economics could strengthen eXoZymes' competitive position for future commercial-scale manufacturing.

FAQ

Frequently asked questions about EXOZ stock

How does Ticker Nerd's model rank EXOZ?

As at 3 Oct 2026, eXoZymes, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).

What is the EXOZ stock forecast for 2030?

No analyst covering eXoZymes, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EXOZ are extrapolating price history, which says nothing about the business.

How has EXOZ stock performed over the past year?

eXoZymes, Inc. returned -58.5% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does eXoZymes, Inc. do?

eXoZymes Inc. is a biotechnology company focused on cell-free biomanufacturing platforms that use AI-enhanced enzymes to produce complex molecules outside living cells.

What is the latest news on EXOZ?

The most recent item we track (TheNewswire, 2 Oct 2026): "Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"". Water Tower Research published an Initiation of Coverage Report on eXoZymes, Inc. (NASDAQ: EXOZ) titled "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity." The report covers the company's cell-free biomanufacturing systems based on engineered enzymes, its history from UCLA research and Invizyne Technologies, its November 2024 IPO, and its pre-revenue status with commercialization expected next year.

Company

About eXoZymes, Inc.

eXoZymes Inc. is a biotechnology company focused on cell-free biomanufacturing platforms that use AI-enhanced enzymes to produce complex molecules outside living cells. The company’s technology is designed to convert affordable feedstocks into high-purity chemicals that are difficult, costly, or inefficient to make through conventional methods. Its current work centers on developing enzyme modules and biocatalytic systems for applications in pharmaceuticals, nutraceuticals, biofuels, and specialty chemicals. By combining synthetic biology, enzyme engineering, and bioreactor-based production, eXoZymes serves markets that require scalable, precise, and adaptable manufacturing solutions. Headquartered in Monrovia, California, eXoZymes positions itself at the intersection of biotechnology and industrial chemistry, supporting the production of valuable molecules used across health, energy, and materials sectors.

CEO Mr. Michael Heltzen · 32 employees · United States · https://www.exozymes.com